KLRB1 and myeloid sarcoma: Still, CD161 is not a TH17-marker, as CD161+ T-cells' production of IFN-γ by far exceeds that of IL-17, and in particular CD161HIGHCD8+ T-cell in MS patients are sensitive to IL-12-induced proliferation and IFN-y production [28].